西妥昔单抗治疗不同性别大肠癌患者的疗效观察

目的:观察西妥昔单抗治疗不同性别大肠癌患者的疗效。方法:回顾性分析我院2013年1月-2014年3月住院手术治疗的表皮生长因子受体(EGFR)阳性的KRAS野生型的大肠癌患者92例,以性别分成男、女两组,均采用FOLFIRI+西妥昔单抗方案治疗,临床病理学特征、治疗效果及不良反应与性别之间的关系。结果:大肠癌患者中男女比例1.42∶1;高分化腺癌男组33例(61.11%)、女组9例(23.68%),中分化腺癌男组9例(16.67%)、女组19例(50.00%),两组间差异均有统计学意义(P<0.05);女组客观有效率(ORR)为34.21%,较男组(14.81%)高(P=0.029),女组疾病控制率(DCR)为73.68%,较男组(50.00%)高(P=0.023),两组间差异均有统计学意义(P<0.05);女组患者治疗后皮疹发生率(57.89%)明显高于男组(33.33%),差异有统计学意义(P=0.019),而其他不良反应在患者性别间的差异均无统计学意义(P>0.05)。结论:大肠癌以男性多见,男组病理学分型高分化腺癌明显高于女组;女性患者在接受FOLFIRI标准化疗+西妥昔单抗治疗后获益更明显;女性大肠癌患者使用西妥昔单抗后更易发生皮疹。

Efficacy Observation of Cetuximab in the Treatment of Colorectal Cancer Patients with Different Gender

OBJECTIVE： To observe therapeutic efficacy of cetuximab in the treatment of colorectal cancer patients with differ- ent gender. METHODS： 92 colorectal cancer patients with positive EGFR and wide-type KRAS gene underwent surgery in our hospital during Jan. 2013--Mar. 2014, were divided into 2 groups by gender. Both groups were given FOLFIRI and cetuximab. The relationship of clinical pathological features, treatment effect and ADR with gender was analyzed comparatively. RESULTS： The proportion of patients with colorectal cancer was 1.42：1 in men and women; there were 33 cases of well differentiated adenocarcinoma in male group （61.11%）, 9 cases in female group （23.68%）; 9 cases of moderate differentiated adenocarcinoma in male group （16.67%）, 19 cases in female group （50.00%）; the difference was statistically significance. ORR （34.21%） of female group was higher than that （14.81%） of male group （P=0.029） ; DCR （73.68%） of female group was higher than that （50.00%） of male group （P=0.023） ; there was statistical significance （P〈0.05） ; the incidence of rash （57.89%） in female group was significantly higher than in male group （33.33%） ; there was statistical significance （P=0.019） ; whereas, the difference of other ADR between male and female had no statistical significance （P〉0.05）. CONCLUSIONS： Coloreetal cancer is more common in male, and the incidence of well differentiated adenocarcinoma of male group is significantly higher than in female group; therapeutic efficacy of female patients is more obvious after receiving FOLFIRI standard chemotherapy＋cetuximab treatment; colorectal cancer female patients are more likely to have rash after receiving cetuximab.